ES2213205T3 - Uso de antagonistas del receptor 5-ht1a para el tratamiento de la incontinencia de orina. - Google Patents

Uso de antagonistas del receptor 5-ht1a para el tratamiento de la incontinencia de orina.

Info

Publication number
ES2213205T3
ES2213205T3 ES97906125T ES97906125T ES2213205T3 ES 2213205 T3 ES2213205 T3 ES 2213205T3 ES 97906125 T ES97906125 T ES 97906125T ES 97906125 T ES97906125 T ES 97906125T ES 2213205 T3 ES2213205 T3 ES 2213205T3
Authority
ES
Spain
Prior art keywords
group
alkyl
aryl
cycloalkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97906125T
Other languages
English (en)
Spanish (es)
Inventor
Amedeo Leonardi
Rodolfo Testa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati SA
Original Assignee
Recordati SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11373430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2213205(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recordati SA filed Critical Recordati SA
Application granted granted Critical
Publication of ES2213205T3 publication Critical patent/ES2213205T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES97906125T 1996-02-28 1997-02-25 Uso de antagonistas del receptor 5-ht1a para el tratamiento de la incontinencia de orina. Expired - Lifetime ES2213205T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI960378 1996-02-28
IT96MI000378A IT1282705B1 (it) 1996-02-28 1996-02-28 Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria

Publications (1)

Publication Number Publication Date
ES2213205T3 true ES2213205T3 (es) 2004-08-16

Family

ID=11373430

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97906125T Expired - Lifetime ES2213205T3 (es) 1996-02-28 1997-02-25 Uso de antagonistas del receptor 5-ht1a para el tratamiento de la incontinencia de orina.

Country Status (10)

Country Link
EP (1) EP0906100B1 (en:Method)
JP (1) JP2001511763A (en:Method)
AT (1) ATE258438T1 (en:Method)
AU (1) AU2093297A (en:Method)
DE (1) DE69727378T2 (en:Method)
DK (1) DK0906100T3 (en:Method)
ES (1) ES2213205T3 (en:Method)
IT (1) IT1282705B1 (en:Method)
PT (1) PT906100E (en:Method)
WO (1) WO1997031637A1 (en:Method)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156780A (en) * 1996-10-17 2000-12-05 Milkhaus Laboratory, Inc. Treatment of fecal incontinence
SE510305C2 (sv) 1997-05-30 1999-05-10 Astra Ab Nytt salt
AU8130298A (en) * 1997-07-15 1999-02-10 Sankyo Company Limited Piperazine derivatives
US6906069B1 (en) 1999-01-08 2005-06-14 Amgen Inc. LXR modulators
AU2000235960A1 (en) * 2000-02-14 2001-08-27 Tularik, Inc. Lxr modulators
US6673543B2 (en) 2000-04-05 2004-01-06 Tularik, Inc. Solid phase synthesis of LXR ligands
DE60216753T2 (de) * 2001-02-16 2008-01-03 Aventis Pharmaceuticals Inc. Heterocyclische harnstoffderivate und deren verwendung als dopamine d3 receptor liganden
CN1558756A (zh) * 2001-09-27 2004-12-29 �ź㴫 用于治疗泌尿疾病的药物组合物
EP1476425A4 (en) 2002-01-30 2010-05-05 Amgen Inc Heterocyclic Aryl Sulphonamidocyclic Compounds
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
JPWO2006082872A1 (ja) * 2005-02-04 2008-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 １−（ピペリジン−４−イル）−１ｈ−インドール誘導体
JP4932717B2 (ja) 2005-05-11 2012-05-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピペリジン環を有するインドール誘導体の製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9201991A (es) * 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
HRP930210A2 (en) * 1992-02-25 1995-06-30 Recordati Chem Pharm Heterobicyclic compounds and pharmaceutical preparations containing them
GB9411099D0 (en) * 1994-06-03 1994-07-27 Wyeth John & Brother Ltd Piperazine derivatives
GB9417135D0 (en) * 1994-08-23 1994-10-12 Medinnova S F Method

Also Published As

Publication number Publication date
DE69727378D1 (de) 2004-03-04
ATE258438T1 (de) 2004-02-15
EP0906100A1 (en) 1999-04-07
AU2093297A (en) 1997-09-16
DK0906100T3 (da) 2004-05-03
JP2001511763A (ja) 2001-08-14
IT1282705B1 (it) 1998-03-31
ITMI960378A0 (en:Method) 1996-02-28
DE69727378T2 (de) 2004-12-09
WO1997031637A1 (en) 1997-09-04
EP0906100B1 (en) 2004-01-28
PT906100E (pt) 2004-06-30
ITMI960378A1 (it) 1997-08-28

Similar Documents

Publication Publication Date Title
ES2213205T3 (es) Uso de antagonistas del receptor 5-ht1a para el tratamiento de la incontinencia de orina.
ES2879826T3 (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares
ES2798138T3 (es) Bloqueadores de los canales de sodio, método de preparación de los mismos y uso de los mismos
US20060293309A1 (en) Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
PT654264E (pt) Tratamento de incontinencia com venlafaxina ou com um composto de ariloxi propanamina
AU4806697A (en) Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
JP2011513484A (ja) 疼痛および掻痒症を治療するための方法、組成物、およびキット
JPS6143113A (ja) 医薬組成物
NO321606B1 (no) Pyrrolderivater og medisinsk sammensetning
EA023267B1 (ru) Способ для лечения и/или предотвращения мигрени
US5990114A (en) Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
CA2525373C (en) Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
AU2017315265B2 (en) Method for treating pruritus and/or itch
Bjorvatn et al. The 5-HT1A receptor antagonist p-MPPI blocks 5-HT1A autoreceptors and increases dorsal raphe unit activity in awake cats
US20210401838A1 (en) Identification of agents displaying functional activation of dopamine d2 and d4 receptors
IE873525L (en) Centrally acting muscle relaxants
JP2004524270A (ja) 長時間作用する麻酔薬および鎮痛薬としての、三環式抗うつ薬およびのそれらのアナログ
JP2004523559A (ja) 過敏性腸症候群および機能性胃腸症の治療方法
ES2808667T3 (es) Derivados de diarilmetilideno piperidina y su uso como agonistas del receptor opioide delta
CN101827816B (zh) Trpv1介导性疾病治疗剂
HUP0303609A2 (hu) Húgyhólyag-túlérzékenység kezelésére alkalmas készítmény
KR20150036115A (ko) 위식도 역류증에 대한 약제
CN119684150A (zh) 牛蒡子苷元衍生物的制备和治疗糖尿病周围神经病变的应用
US20050130982A1 (en) Oral therapeutic or preventative drugs for pollakiuria and urinary incontinence and oral sleep inducers, containing tropolone derivatives
CN114159568A (zh) Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用